This inventor holds 25 USPTO granted patents and 9 published patent applications, plus 2 CIPO patents and 8 EPO patents, primarily in Cardiovascular Biomarkers. Top assignees: Zora Biosciences Oy, Baker Heart and Diabetes Institute. Active years: 2009-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Lampäälä, FI (2017)
- Lempaala, FI (2016 - 2019)
- Lempäälä, FI (2009 - 2020)
- Lampaeaelae, FI (2021)
- Lempaeaelae, FI (2022 - 2024)
Company Filing History:

Years Active: 2009-2025
Areas of Expertise:
Title: The Innovations of Reijo Laaksonen: Pioneering Patents in Cardiovascular Disease
Introduction: Reijo Laaksonen, a distinguished inventor located in Lempäälä, Finland, has made significant contributions to the field of medical science with a remarkable portfolio of 22 patents. His work primarily focuses on innovations addressing cardiovascular diseases, particularly through the analysis of lipidomic biomarkers.
Latest Patents: Among Laaksonen's latest patents are groundbreaking inventions that aim to enhance the diagnosis and prediction of atherosclerosis and cardiovascular disease (CVD). His method involves detecting specific lipid concentrations or ratios in biological samples, comparing them to control samples, and has identified unique lipid markers that are notably more sensitive and specific than existing clinical indicators. This invention also includes antibodies targeting these lipids, along with kits designed for predicting, diagnosing, preventing, and treating atherosclerosis or CVD.
Another notable patent details the use of ceramides in predicting cardiovascular complications. This invention outlines a method for predicting complications such as acute myocardial infarction (AMI), acute coronary syndrome (ACS), stroke, and cardiovascular-related deaths by measuring concentrations of specific ceramides in biological samples and analyzing them against a control. Identifying decreased levels of Group A ceramides and increased levels of Group B ceramides can indicate an elevated risk of developing these complications.
Career Highlights: Reijo Laaksonen's career at Zora Biosciences Oy has been marked by a continuous pursuit of innovation in the medical research sector. His dedication to advancing healthcare diagnostics showcases his commitment to improving patient outcomes through science and research.
Collaborations: Throughout his career, Laaksonen has collaborated with esteemed professionals, including Reini Hurme and Kim Ekroos. These partnerships have enabled him to amalgamate expertise and enhance research efforts in the realms of cardiovascular health and lipidomics.
Conclusion: Reijo Laaksonen stands out as a leading inventor whose innovative patents have the potential to significantly alter the landscape of cardiovascular disease diagnosis and treatment. His work at Zora Biosciences Oy exemplifies a profound commitment to health innovations that will benefit patients and healthcare providers alike.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile